Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
25 avr. 2017 08h00 HE
|
Galectin Therapeutics
NORCROSS, Ga., April 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin...
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update
28 mars 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., March 28, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Present at 29th Annual ROTH Conference
09 mars 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., March 09, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Galectin Therapeutics to Present at BIO CEO & Investor Conference
08 févr. 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial
01 févr. 2017 08h10 HE
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated...
Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders
08 déc. 2016 08h00 HE
|
Galectin Therapeutics
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company...
Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases
10 nov. 2016 08h00 HE
|
Galectin Therapeutics
NORCROSS, Ga., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced its plans to...
Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia
17 oct. 2016 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis
07 oct. 2016 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
31 août 2016 08h00 HE
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...